Industrifonden has sold its entire holding in the medical technology company CellaVision, corresponding to 15 percent of the capital and votes.
CellaVision develops and sells instruments for digital analysis of blood and other body fluids. Its customers include clinical laboratories, usually in large hospitals, which, using CellaVision’s instruments, can improve and raise the efficiency of routines that had previously been done manually.
CellaVison has customers in around 50 countries and subsidiaries in the US, Canada and Japan. Exports account for the large share of sales. The company, which is listed on NASDAQ Stockholm, has had strong growth in recent years.
Industrifonden has been involved with CellaVision since 2000, first as a lender and then as a shareholder. With its 15 percent of the capital and votes, the Fund was the largest shareholder in the company.
“For 15 years we have participated actively in building CellaVision from a small research firm into an internationally well-positioned medical technology company,” says Lars Henriksson, Investment Manager at Industrifonden. “The company’s future is bright, but our role is completed. Thanks to this successful investment, we now have the capital for new investments.
Industrifonden’s shareholding attracted strong institutional interest and was placed with Swedish and international investors, including a number of existing shareholders. The sale of the shares was executed by ABG Sundal Collier.